Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2007

View Archived Issues

Combining tiotropium and fluticasone-salmeterol beneficial in COPD

AM-111 otoprotective in acute labyrinthitis model

Diverse immune responses seen with full-length p53 antigen-expressing vaccine

Myxoma virus: A novel viral oncolytic approach in hard to treat cancers

Targeted nanoparticles found effective in premalignant epithelial neoplasia

Interferon/gemcitabine-based adjuvant therapy improves survival, toxicity remains a concern

Zogenix closes USD 10 million financing deal

Enrollment completed in phase III Alzheimer's trial of Flurizan

CUV-1647 to be studied for prevention of phototoxicity in PDT

SPA filing for phase III study of Xyotax plus carboplatin in women with NSCLC

Pain Therapeutics cleared for Israeli phase I metastatic melanoma study

New data suggest utility of Homspera as cotherapeutic agent

Dharma's IDDS effective in reducing pain in phase II study

Updated interim antibody reduction data reported for Riquent

Cannasat and IntelGenx to codevelop novel cannabinoid-based product

Combination studies with sorafenib to continue after positive findings

Radius' hPTHrP analogue begins phase II testing for osteoporosis

Enrollment open in phase I/II study of plasmin for acute PAO

Potential applications for Unigene's site-directed bone growth technology

GenVec and NIAID sign CRADA for RSV vaccine development

Pharmatek to manufacture ANX-201 for clinical studies

No causal link between neuropsychiatric symptoms and treatment with Tamiflu

Aquavan provides successful sedation in patients undergoing bronchoscopy

Japanese approval for Risperdal OD

Novel agents are reported for use in the treatment of genitourinary disorders

Novel treatments for psychological disorders claimed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...